Abstract
Human melanoma cells can process the MAGE-1 gene product and present the processed nonapeptide EADPTGHSY on their major histocompatibility complex class I molecules, HLA-A1, as a determinant for cytolytic T lymphocytes (CTLs). Considering that autologous antigen presenting cells (APCs) pulsed with the synthetic nonapeptide might, therefore, be immunogenic, melanoma patients whose tumor cells express the MAGE-1 gene and who are HLA-A1+ were immunized with a vaccine made of cultured autologous APCs pulsed with the synthetic nonapeptide. Analyses of the nature of the in vivo host immune response to the vaccine revealed that the peptide-pulsed APCs are capable of inducing autologous melanoma-reactive and the nonapeptide-specific CTLs in situ at the immunization site and at distant metastatic disease sites.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Amino Acid Sequence
-
Antigen-Presenting Cells / immunology*
-
Antigens, Neoplasm / biosynthesis*
-
Cell Line
-
Gene Expression
-
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
-
HLA-A1 Antigen / analysis
-
HLA-A1 Antigen / biosynthesis
-
HLA-A1 Antigen / chemistry
-
Humans
-
Immunophenotyping
-
Immunotherapy / methods
-
Lymphocytes, Tumor-Infiltrating / immunology
-
Melanoma / immunology*
-
Melanoma / therapy
-
Melanoma-Specific Antigens
-
Molecular Sequence Data
-
Neoplasm Proteins*
-
Peptide Fragments / immunology*
-
Polymerase Chain Reaction
-
Recombinant Proteins / pharmacology
-
T-Lymphocytes, Cytotoxic / immunology*
-
Tumor Cells, Cultured
-
Vaccines, Synthetic / immunology*
Substances
-
Antigens, Neoplasm
-
HLA-A1 Antigen
-
MAGEA1 protein, human
-
Melanoma-Specific Antigens
-
Neoplasm Proteins
-
Peptide Fragments
-
Recombinant Proteins
-
Vaccines, Synthetic
-
Granulocyte-Macrophage Colony-Stimulating Factor